Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them.

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.

There’s a new wave of demand as pathology and AI propel precision medicine forward. Our traction has proven that we can rewire pathology for this paradigm shift and help our customers remain at the ...

Basel: Roche has announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) ...

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma ...

With Guam's longtime and only pathologist, Dr. Mohammed Alsabban is set to retire in the coming months, there’s been some ...

Scopio Labs announced today its strategic alliance with Siemens Healthineers has expanded to include the global distribution of Scopio's Full-Field Bone Marrow Aspiratetm (FF-BMA) Application*, the ...